La Clinique du Sommeil
La Clinique du Sommeil
All news
Clinical study

A new orexin receptor agonist shows promise for narcolepsy

A study evaluated the orexin receptor 2 agonist, alixorexton, for type 1 narcolepsy. This treatment showed significant improvements in alertness and cataplexy. Side effects were generally tolerable, paving the way for further studies.

A new orexin receptor agonist shows promise for narcolepsy

What is alixorexton?

Alixorexton is a medication that acts on orexin receptors, proteins involved in the regulation of wakefulness. This study examined its efficacy and safety in adults with type 1 narcolepsy.

Study results

In this study, 92 participants received either alixorexton at different doses or a placebo for 6 weeks. The results showed that those taking alixorexton had significant improvements in sleep latency, meaning they stayed awake longer.

Observed side effects

The most common side effects in participants taking alixorexton included urinary issues, insomnia, and hypersalivation. These effects were generally considered tolerable and consistent with the known effects of orexin receptor agonists.

What does this mean for patients?

The results of this study are encouraging for individuals with type 1 narcolepsy, as they suggest that alixorexton could offer a new treatment option. However, it is important to note that further studies are needed to confirm these results and assess long-term safety.

This article is provided for information only and does not replace medical advice. For any question about your own situation, talk to your doctor.